Breaking News

Penn Pharma Signs Multiple Clients

By Gil Roth | November 18, 2013

Exceeds expectations with new containment facility

Penn Pharma has secured multiple contracts with companies in Europe, the U.S., and Japan less than two months after officially opening the doors of its new high potency manufacturing facility.
 
The facility was designed to meet the growing market need for contained manufacturing processes. According to a company statement, "Successfully securing multiple global contracts in such a short space of time has verified Penn’s vision and investment strategy that led to the design and build of this new state-of-the-art facility." Penn announced its plans to build the new facility in 2012 and the first batch of coated tablets were produced in May of this year.
 
Richard Yarwood, Penn Pharma’s chief executive officer, commented, “Our vision is to become the preferred partner for the supply of oral doses containing potent molecules for both investigational and commercial use, and this facility will help us to achieve this."
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks